Retatrutide is emerging as one of the most closely watched weight-loss peptides thanks to its powerful triple-agonist mechanism, which early research suggests may outperform today’s leading drugs like semaglutide and tirzepatide. While early trials show impressive reductions in appetite, improved metabolic markers and significant weight loss, the medication is not yet available and still undergoing extensive safety testing. Its potential is enormous, but questions remain about long-term side effects, accessibility and whether results will hold up in broader, real-world populations.